Symbols

MDWD

MediWound·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Ample Liquidity

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MDWD

Mediwound Ltd.

A fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration

Industry

Pharmaceutical

Established Date

01/27/2000

Listing Date

03/20/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

121

Fiscal Year Ends

12-31

Website

www.mediwound.com

Security Type

Common stock

Office address

42 Hayarkon Street, Yavne , 8122745 Israel

Business

Introduction

MediWound Ltd., was legally incorporated in Israel on January 27, 2000. The company is a global leader in next-generation enzyme therapies focused on non-surgical tissue repair. The company's solution selectively removes inactive and dangerous tissue while preserving healthy tissue, providing a safer and more effective alternative to traditional methods. With strong internal research, development and manufacturing capabilities, the company manufactures and commercializes cutting-edge biologics for wound and burn care that exceed existing standards of care, improve patient prognosis, and reduce healthcare costs by eliminating the need for surgical intervention.

Company Financials

EPS

MDWD has released its 2025 Q4 earnings. EPS was reported at -0.56, versus the expected -0.59, beating expectations. The chart below visualizes how MDWD has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MDWD has released its 2025 Q4 earnings report, with revenue of 1.87M, reflecting a YoY change of -68.03%, and net profit of -7.18M, showing a YoY change of -83.80%. The Sankey diagram below clearly presents MDWD's revenue sources and cost distribution.